Enovis (ENOV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.90
- Estimate
- $0.85
- Surprise
- +6.3%
- Revenue (period 2026-07-03)
- $582.8M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
Enovis (ENOV) beat the $0.85 estimate with diluted EPS of $0.90 — a clear 6.3% upside surprise. TrendMatrix's engine moved from Hold (6.2/10) to Buy (Wait) at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ENOV Sell at 6.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.3% surprise compares with a +11.2% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Risk below floor (2.3 < 3.0)
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.40
- Price target
- $33.35
- Stop
- $18.49
- Upside to target
- +71.9%
- Reward-to-risk
- 5.0:1
Risk check: RSI 20 — a level conventionally read as oversold; trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ENOV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.12B
- P/E (fwd)
- 5.3
- 52-week range
- $19.06–$34.28
- Off 52-week high
- 43.4%
- RSI (14)
- 20
- Volume vs avg
- 1.94×
- Score today
- 6.0/10